Search results for "hate"

showing 10 items of 2099 documents

Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues

2018

Abstract Background: The role of bone marrow response in patients with immune thrombocytopenia (ITP) has gained paramount importance since the last 10 years, with the demonstrations that marrow megakaryocytes (MGK) are unable to properly compensate platelets peripheral destruction. TPO receptor agonists (TPOa), namely romiplostim (ROMI) and eltrombopag (EPAG), by stimulating megakaryopoiesis are able to induce a response in 74% to 94% of cases in clinical trials. However, real world use of these drugs has shown frequent changes in individual dose requirement, the possibility of treatment discontinuation, and their effectiveness outside registered indications; moreover, nothing is known abou…

medicine.medical_specialtyRomiplostimbusiness.industryImmunologyEltrombopagAzathioprineCell BiologyHematologymedicine.diseaseBiochemistryInosine triphosphatechemistry.chemical_compoundchemistryDysplasiaInternal medicineCohortmedicineMiddle-aged adultbusinessAdverse effectmedicine.drugBlood
researchProduct

Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular s…

2021

Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM), and ferumoxytol (FER), are successful treatments for iron deficiency (Europe; FDI and FCM) and iron deficiency anemia (US; FDI, FCM, and FER).Areas covered: This review focusses on the chemistry and structure of FDI, FCM, and FER, and on three key aspects of IV iron safety: (1) hypersensitivity; (2) hypophosphatemia and sequelae; (3) cardiovascular safety.Expert opinion: Although the safety of modern IV iron has improved, immediate in…

medicine.medical_specialtySide effectAnemiaHypophosphatemia030204 cardiovascular system & hematologyDrug Hypersensitivity03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Intensive care medicineAnemia Iron-Deficiencybusiness.industryGeneral MedicineIron deficiencymedicine.diseaseFerumoxytolIron-deficiency anemiaCardiovascular Diseases030220 oncology & carcinogenesisFerricAdministration IntravenousbusinessAnaphylaxisHypophosphatemiaIron Compoundsmedicine.drugExpert opinion on drug safety
researchProduct

Increased susceptibility to lipid peroxidation in skeletal muscles of dystrophic hamsters.

1989

The results showed that the total content of lipids, which could be peroxidized with Fe(2 +)/ascorbate stimulation in vitro, was 45.4% and 53.7% higher than normal in the dystrophic hamster muscle at the age of 1 and 3 months, respectively. Correspondingly, the susceptibility to lipid peroxidation (stimulated by ADP-chelated iron at 37 degrees C) was 38.6-74.3% higher in dystrophic muscles. The increases were not related to necrotic lesions and inflammation observed. The activities of glucose-6-phosphate dehydrogenase, glutathione reductase, thioredoxin reductase and catalase were increased in dystrophic muscles but those of superoxide dismutases and glutathione peroxidase were unaffected.

medicine.medical_specialtyThioredoxin-Disulfide ReductaseThioredoxin reductaseGlutathione reductaseHamsterStimulationGlucosephosphate DehydrogenaseAntioxidantsLipid peroxidationSuperoxide dismutaseCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicineCricetinaemedicineAnimalsMolecular BiologyCreatine KinasePharmacologychemistry.chemical_classificationGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidaseMusclesCell BiologyMuscular Dystrophy AnimalMolecular biologyEndocrinologyGlutathione ReductasechemistryCatalasebiology.proteinMolecular MedicineLipid PeroxidationExperientia
researchProduct

Differential effects of oxidized LDL on apolipoprotein AI and B synthesis in HepG2 cells

2006

Oxidized low-density lipoproteins (Ox-LDL) are key elements in atherogenesis. Apolipoprotein AI (apoAI) is an active component of the antiatherogenic high-density lipoproteins (HDL). In contrast, plasma apolipoprotein B (apoB), the main component of LDL, is highly correlated with coronary risk. Our results, obtained in HepG2 cells, show that Ox-LDL, unlike native LDL, leads to opposite effects on apoB and apoAI, namely a decrease in apoAI and an increase in apoB secretion as evaluated by [(3)H]leucine incorporation and specific immunoprecipitation. Parallel pulse-chase studies show that Ox-LDL impaired apoB degradation, whereas apoAI degradation was increased and mRNA levels were decreased.…

medicine.medical_specialtyTime FactorsFree RadicalsApolipoprotein BImmunoprecipitationBiochemistryCell Linechemistry.chemical_compoundLeucinePhysiology (medical)Lipid biosynthesisInternal medicinemedicineHumansSecretionRNA MessengerTriglyceridesGlyceraldehyde 3-phosphate dehydrogenaseApolipoproteins BApolipoprotein A-IbiologyCholesterolnutritional and metabolic diseasesAtherosclerosisLipidsMOPSLipoproteins LDLOxygenEndocrinologychemistryCell culturebiology.proteinlipids (amino acids peptides and proteins)Cholesterol EstersFree Radical Biology and Medicine
researchProduct

Oxygen and substrate deprivation on isolated rat cardiac myocytes : temporal relationship between electromechanical and biochemical consequences

1990

The effects of hypoxia and reoxygenation on action potentials (AP), contractions, and certain biochemical parameters were studied in isolated rat ventricular myocytes in monolayer culture in the presence and absence of glucose. Substrate deprivation alone had no influence on the basal properties. In the presence of glucose, a 4-h hypoxic treatment caused only a moderate decrease in AP amplitude and rate. In substrate-free conditions, hypoxia induced a gradual decline in plateau potential level and in AP duration and rate, followed by rhythm abnormalities and a failure of the electromechanical coupling. Spontaneous AP generation then ceased, and the resting potential decreased with increase…

medicine.medical_specialtyTime FactorsPhysiology[SDV]Life Sciences [q-bio]Action Potentialschemistry.chemical_element030204 cardiovascular system & hematologyBiologyGLYCOSEACIDE LACTIQUEOxygenMembrane PotentialsContractility03 medical and health sciencesAdenosine Triphosphate0302 clinical medicinePhysiology (medical)Internal medicinemedicineAnimalsMyocyteHypoxiaCells Cultured030304 developmental biologyPharmacologyFREQUENCE0303 health sciencesL-Lactate DehydrogenaseMyocardiumRats Inbred StrainsBiological activityGeneral MedicineHypoxia (medical)Myocardial ContractionRatsElectrophysiologyATP[SDV] Life Sciences [q-bio]ElectrophysiologyGlucoseEndocrinologychemistryCell cultureCirculatory systemLactatesBiophysicsRATmedicine.symptom
researchProduct

Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.

2011

Introduction: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, desmoglein-1 and -3. Before the advent of corticosteroids, therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to similar to 10%, but long-term use of steroids can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the patient's cumulative exposure to systemic corticosteroids. Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have …

medicine.medical_specialtyToxicologyMycophenolateMycophenolic acidPharmacokineticsAdrenal Cortex HormonesmedicineInitial treatmentimmunosuppressant inosine monophosphate dehydrogenase mycophenolate mofetil mycophenolic acid pemphigus pharmacokinetic treatmentHumansPharmacologyintegumentary systembusiness.industryMortality rateAutoantibodyGeneral MedicineMycophenolic Acidmedicine.diseaseDermatologyPemphigusImmunologybusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering diseaseExpert opinion on drug metabolismtoxicology
researchProduct

The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder dis…

2014

Highlights • Muscarinic receptors increase smooth muscle tone in airways and urinary bladder. • β-Adrenoceptors relax smooth muscle tone and oppose muscarinic contraction. • Opposition involves transmitter release, signal transduction and receptor expression. • This supports the combined use of muscarinic antagonists and β-adrenoceptor agonists.

medicine.medical_specialtyUrologyDiseaseMuscarinic AntagonistsPharmacologyArticleβ adrenoceptorchemistry.chemical_compoundInternal medicineReceptors Adrenergic betaMuscarinic acetylcholine receptorDrug DiscoveryMuscarinic acetylcholine receptor M4RAT URINARY-BLADDERMedicineAnimalsHumansCyclic adenosine monophosphateADRENERGIC RELAXATIONLung Diseases ObstructivePROTEIN-KINASE-CReceptorTRACHEAL SMOOTH-MUSCLEPharmacologybusiness.industryUrinary Bladder DiseasesMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2ACETYLCHOLINE-RELEASEAdrenergic beta-Agonistsmedicine.diseaseReceptors MuscarinicEndocrinologyNONNEURONAL CHOLINERGIC SYSTEMchemistryGUINEA-PIG TRACHEADrug Therapy CombinationCYCLIC ADENOSINE-MONOPHOSPHATECA2+-ACTIVATED K+ CHANNELAirwaybusinessUrinary bladder diseaseAUTORADIOGRAPHIC VISUALIZATIONAcetylcholinemedicine.drug
researchProduct

Vasoactive intestinal peptide stimulation of cyclic guanosine monophosphate formation: further evidence for a role of nitric oxide synthase and cytos…

1993

In the rat pineal gland vasoactive intestinal peptide (VIP) and beta-adrenergic agonists stimulate cyclic guanosine monophosphate (cGMP) formation and their action is amplified by alpha 1-adrenergic agonists. Since beta-adrenergic stimulation of cGMP is suggested to involve activation of nitric oxide (NO) synthase and NO-mediated activation of cytosolic guanylate cyclase (GC), we investigated the effects of the NO synthase inhibitor N-monomethyl-L-arginine (L-NMMA) and of the cytosolic GC inhibitor methylene blue (MB) on VIP receptor-stimulated cGMP formation. Both L-NMMA and MB depressed VIP-induced cGMP formation as well as alpha 1-adrenergic potentiation of VIP-stimulated cGMP formation …

medicine.medical_specialtyVasoactive intestinal peptideArgininePineal GlandPinealocyteNitric oxidechemistry.chemical_compoundPhenylephrineEndocrinologyCytosolInternal medicinemedicineAnimalsCyclic guanosine monophosphateCyclic GMPomega-N-MethylarginineATP synthasebiologyDrug SynergismRatsNitric oxide synthaseMethylene BlueEndocrinologychemistryGuanylate CyclaseSecond messenger systembiology.proteinOmega-N-MethylarginineAmino Acid OxidoreductasesNitric Oxide Synthasehormones hormone substitutes and hormone antagonistsVasoactive Intestinal PeptideEndocrinology
researchProduct

Fibrinogen and von Willebrand factor in type II diabetes mellitus

1992

A hypercoagulable state may contribute to the formation of early vascular lesions in diabetes. The von Willebrand factor is required for the attachment of platelets to the subendothelium; fibrinogen is required for platelet aggregation. This study was designed to assess in type II diabetic patients plasma levels of fibrinogen and von Willebrand factor to see if these variables are associated with platelet aggregation responses to adenosine diphosphate (ADP). Fibrinogen and the von Willebrand factor were significantly increased in diabetics but only fibrinogen was significantly related to platelet aggregation for ADP. Strict metabolic control does not reduce the increased concentrations of t…

medicine.medical_specialtybiologybusiness.industryEndocrinology Diabetes and MetabolismGeneral MedicineFibrinogenmedicine.diseaseAdenosine diphosphatechemistry.chemical_compoundEndocrinologyEndocrinologychemistryVon Willebrand factorInternal medicineMetabolic control analysisDiabetes mellitusInternal Medicinebiology.proteinMedicinePlateletRisk factorbusinessmedicine.drugMacrovascular diseaseActa Diabetologica
researchProduct

Der Effekt von Neostigmin an der motorischen Endplatte beim Intermediärsyndrom der Alkylphosphatvergiftung

1991

A patient with severe organophosphate intoxication received Neostigmine 1 mg IV during the intermediate syndrome. This dose resulted clinically and neurophysiologically in a marked deterioration of neuro-muscular transmission. This effect of neostigmine on the neuromuscular block during the intermediate syndrome (deterioration) differs from its effect on a similar pattern (improvement), which is seen in the delayed neuropathy following organophosphate exposure. The administration of therapeutic doses of cholinesterase inhibitors in patients with a reduced safety margin due to inhibition of endplate acetylcholinesterase may be dangerous.

medicine.medical_specialtybiologybusiness.industryOrganophosphateNeuromuscular transmissionmedicine.diseaseOrganophosphate poisoningAcetylcholinesteraseNeostigminechemistry.chemical_compoundEndocrinologyMotor EndplatechemistryEnzyme inhibitorPhysiology (medical)AnesthesiaInternal medicinemedicinebiology.proteinNeurology (clinical)businessmedicine.drugCholinesteraseKlinische Neurophysiologie
researchProduct